Patient characteristics.
| Variables | N (%) |
|---|---|
| N | 263 |
| Age, median years (range) | 62 (18–87) |
| Sex | |
| Male | 141 (53.6) |
| Female | 122 (46.4) |
| Diagnosis | |
| Hodgkin lymphoma | 11 (4.2) |
| Diffuse large B-cell lymphoma | 179 (68.1) |
| Follicular lymphoma | 13 (4.9) |
| Mantle cell lymphoma | 8 (3.0) |
| NK/T-cell lymphoma | 14 (5.3) |
| Angioimmunoblastic T-cell lymphoma | 19 (7.2) |
| Peripheral T-cell lymphoma | 13 (4.9) |
| Anaplastic large cell lymphoma | 6 (2.3) |
| Ann Arbor staging | |
| I | 41 (15.6) |
| II | 62 (23.6) |
| III | 74 (28.1) |
| IV | 86 (32.7) |
| Prognostic risk groupa) | |
| Low risk | 97 (36.9) |
| Low-intermediate risk | 71 (27.0) |
| High-intermediate risk | 62 (23.6) |
| High risk | 33 (12.5) |
| Positive serum EBV DNA | 79 (30.0) |
| Relapse/refractory | 67 (25.5) |
| Death | 65 (24.7) |
a)The International Prognostic Index (IPI) was used for non-Hodgkin lymphoma. The International Prognostic Score (IPS) was adjusted for patients with Hodgkin lymphoma, and IPS 0 and 1 were classified as low risk, 2 as low-intermediate, 3 as high-intermediate, and ≥4 as high-risk group in this analysis.
Abbreviations: EBV, Epstein–Barr virus; NK/T, natural killer T.
Blood Res 2021;56:65~71 https://doi.org/10.5045/br.2021.2021028
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd